Contrast Ultrasound Assessment of Skeletal Muscle Recruitable Perfusion after Permanent Left Ventricular Assist Device Implantation: Implications for Functional Recovery.
Contrast-enhanced ultrasound
Heart failure
Left ventricular assist device
Muscle blood flow
Journal
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
ISSN: 1097-6795
Titre abrégé: J Am Soc Echocardiogr
Pays: United States
ID NLM: 8801388
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
02
11
2021
revised:
17
12
2021
accepted:
21
12
2021
pubmed:
2
1
2022
medline:
10
5
2022
entrez:
1
1
2022
Statut:
ppublish
Résumé
In heart failure with reduced ejection fraction (HFrEF), abnormal regulation of skeletal muscle perfusion contributes to reduced exercise tolerance. The aim of this study was to test the hypothesis that improvement in functional status after permanent left ventricular assist device (LVAD) implantation in patients with HFrEF is related to improvement in muscle perfusion during work, which was measured using contrast-enhanced ultrasound (CEUS). CEUS perfusion imaging of calf muscle at rest and during low-intensity plantar flexion exercise (20 W, 0.2 Hz) was performed in patients with HFrEF (n = 22) at baseline and 3 months after placement of permanent LVADs. Parametric analysis of CEUS data was used to quantify muscle microvascular blood flow (MBF), blood volume index, and red blood cell flux rate. For subjects alive at 3 months, comparisons were made between those with New York Heart Association functional class I or II (n = 13) versus III or IV (n = 7) status after LVAD. Subjects were followed for a median of 5.7 years for mortality. Echocardiographic data before and after LVAD placement and LVAD parameters were similar in subjects classified with New York Heart Association functional class I-II versus functional class III-IV after LVAD. Skeletal muscle MBF at rest and during exercise before LVAD implantation was also similar between groups. After LVAD placement, resting MBF remained similar between groups, but during exercise those with New York Heart Association functional class I or II had greater exercise MBF (111 ± 60 vs 52 ± 38 intensity units/sec, P = .03), MBF reserve (median, 4.45 [3.95 to 6.80] vs 2.22 [0.98 to 3.80]; P = .02), and percentage change in exercise MBF (median, 73% [-28% to 83%] vs -45% [-80% to 26%]; P = .03). During exercise, increases in MBF were attributable to faster microvascular flux rate, with little change in blood volume index, indicating impaired exercise-mediated microvascular recruitment. The only clinical or echocardiographic feature that correlated with post-LVAD exercise MBF was a history of diabetes mellitus. There was a trend toward better survival in patients who demonstrated improvement in muscle exercise MBF after LVAD placement (P = .05). CEUS perfusion imaging can quantify peripheral vascular responses to advanced therapies for HFrEF. After LVAD implantation, improvement in functional class is seen in patients with improvements in skeletal muscle exercise perfusion and flux rate, implicating a change in vasoactive substances that control resistance arteriolar tone.
Sections du résumé
BACKGROUND
In heart failure with reduced ejection fraction (HFrEF), abnormal regulation of skeletal muscle perfusion contributes to reduced exercise tolerance. The aim of this study was to test the hypothesis that improvement in functional status after permanent left ventricular assist device (LVAD) implantation in patients with HFrEF is related to improvement in muscle perfusion during work, which was measured using contrast-enhanced ultrasound (CEUS).
METHODS
CEUS perfusion imaging of calf muscle at rest and during low-intensity plantar flexion exercise (20 W, 0.2 Hz) was performed in patients with HFrEF (n = 22) at baseline and 3 months after placement of permanent LVADs. Parametric analysis of CEUS data was used to quantify muscle microvascular blood flow (MBF), blood volume index, and red blood cell flux rate. For subjects alive at 3 months, comparisons were made between those with New York Heart Association functional class I or II (n = 13) versus III or IV (n = 7) status after LVAD. Subjects were followed for a median of 5.7 years for mortality.
RESULTS
Echocardiographic data before and after LVAD placement and LVAD parameters were similar in subjects classified with New York Heart Association functional class I-II versus functional class III-IV after LVAD. Skeletal muscle MBF at rest and during exercise before LVAD implantation was also similar between groups. After LVAD placement, resting MBF remained similar between groups, but during exercise those with New York Heart Association functional class I or II had greater exercise MBF (111 ± 60 vs 52 ± 38 intensity units/sec, P = .03), MBF reserve (median, 4.45 [3.95 to 6.80] vs 2.22 [0.98 to 3.80]; P = .02), and percentage change in exercise MBF (median, 73% [-28% to 83%] vs -45% [-80% to 26%]; P = .03). During exercise, increases in MBF were attributable to faster microvascular flux rate, with little change in blood volume index, indicating impaired exercise-mediated microvascular recruitment. The only clinical or echocardiographic feature that correlated with post-LVAD exercise MBF was a history of diabetes mellitus. There was a trend toward better survival in patients who demonstrated improvement in muscle exercise MBF after LVAD placement (P = .05).
CONCLUSIONS
CEUS perfusion imaging can quantify peripheral vascular responses to advanced therapies for HFrEF. After LVAD implantation, improvement in functional class is seen in patients with improvements in skeletal muscle exercise perfusion and flux rate, implicating a change in vasoactive substances that control resistance arteriolar tone.
Identifiants
pubmed: 34973393
pii: S0894-7317(21)00886-5
doi: 10.1016/j.echo.2021.12.014
pmc: PMC9081119
mid: NIHMS1767869
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-502Subventions
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL078610
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130046
Pays : United States
Informations de copyright
Copyright © 2021 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.
Références
Circulation. 1998 Feb 10;97(5):473-83
pubmed: 9490243
J Appl Physiol (1985). 2001 Jan;90(1):55-61
pubmed: 11133893
Diabetes. 1997 Sep;46(9):1381-8
pubmed: 9287035
Echocardiography. 2017 Aug;34(8):1187-1194
pubmed: 28664576
Exp Physiol. 2014 Apr;99(4):609-15
pubmed: 24293507
J Physiol. 2021 Feb;599(3):889-910
pubmed: 31977068
Am J Physiol. 1985 Aug;249(2 Pt 2):H386-92
pubmed: 4025569
Circulation. 1999 Apr 27;99(16):2113-7
pubmed: 10217650
J Am Soc Echocardiogr. 2019 Sep;32(9):1086-1094.e3
pubmed: 31235422
J Am Coll Cardiol. 2009 Jun 9;53(23):2175-83
pubmed: 19497445
Int J Cardiol. 2015 Jan 15;178:232-8
pubmed: 25464261
J Clin Invest. 1991 Dec;88(6):2077-82
pubmed: 1752965
Hypertension. 2012 Sep;60(3):659-68
pubmed: 22753215
Heart Fail Rev. 2013 Sep;18(5):623-30
pubmed: 23065040
Circulation. 2017 Mar 28;135(13):1240-1252
pubmed: 28174191
Front Physiol. 2019 Feb 21;10:129
pubmed: 30846944
Am J Physiol Heart Circ Physiol. 2014 Nov 15;307(10):H1512-20
pubmed: 25260608
J Appl Physiol (1985). 2003 Sep;95(3):1055-62
pubmed: 12740313
Br J Haematol. 2017 Nov;179(4):648-656
pubmed: 28880374
Circulation. 2009 Jan 6;119(1):62-70
pubmed: 19075104
Am J Physiol Regul Integr Comp Physiol. 2019 May 1;316(5):R512-R524
pubmed: 30789790
Diabetes. 2018 Sep;67(9):1729-1741
pubmed: 30135134
JACC Cardiovasc Imaging. 2008 May;1(3):343-50
pubmed: 19356447
JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 1):1430-1440
pubmed: 29909101
Compr Physiol. 2015 Sep 20;5(4):1947-69
pubmed: 26426472
Heart Fail Rev. 2017 Mar;22(2):149-166
pubmed: 27392715
World J Cardiol. 2010 Nov 26;2(11):377-90
pubmed: 21179305
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1050-63
pubmed: 22101528
Circulation. 2005 Jan 25;111(3):310-4
pubmed: 15655134
J Card Fail. 2016 Oct;22(10):797-805
pubmed: 26777757
JACC Heart Fail. 2015 Sep;3(9):703-11
pubmed: 26277768
Diabetes. 2006 May;55(5):1436-42
pubmed: 16644702